These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36847968)

  • 21. Deficiency of Biogenic Amines Modulates the Activity of Hypoglossal Nerve in the Reserpine Model of Parkinson's Disease.
    Jampolska M; Andrzejewski K; Zaremba M; Joniec-Maciejak I; Kaczyńska K
    Cells; 2021 Mar; 10(3):. PubMed ID: 33801475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    Hill MP; Brotchie JM
    Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain.
    Bilska A; Dubiel M; Sokołowska-Jezewicz M; Lorenc-Koci E; Włodek L
    Neuroscience; 2007 Jun; 146(4):1758-71. PubMed ID: 17478054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal development of neurochemical and cognitive impairments following reserpine administration in rats.
    Pereira AG; Poli A; Matheus FC; de Bortoli da Silva L; Fadanni GP; Izídio GS; Latini A; Prediger RD
    Behav Brain Res; 2020 Apr; 383():112517. PubMed ID: 32006562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
    Wang MH; Lin RF; Tseng HC; Soung HS; Chang KC; Tsai CC
    Pharmacol Biochem Behav; 2015 Apr; 131():71-6. PubMed ID: 25668129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
    Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardamom oil ameliorates behavioral and neuropathological disorders in a rat model of depression induced by reserpine.
    Abdel-Rasoul AA; Saleh NA; Hosny EN; El-Gizawy MM; Ibrahim EA
    J Ethnopharmacol; 2023 May; 308():116254. PubMed ID: 36781058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
    Burger ME; Alves A; Callegari L; Athayde FR; Nogueira CW; Zeni G; Rocha JB
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):135-40. PubMed ID: 12551736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinson's Disease.
    Lima AC; Meurer YSR; Bioni VS; Cunha DMG; Gonçalves N; Lopes-Silva LB; Becegato M; Soares MBL; Marinho GF; Santos JR; Silva RH
    Front Aging Neurosci; 2021; 13():757714. PubMed ID: 34759815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in the progressive model of parkinsonism induced by reserpine in rats.
    Bispo JMM; Melo JEC; Gois AM; Leal PC; Lins LCRF; Souza MF; Medeiros KAAL; Ribeiro AM; Silva RH; Marchioro M; Santos JR
    Behav Brain Res; 2019 May; 363():23-29. PubMed ID: 30690108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebellar neurochemical and histopathological changes in rat model of Parkinson's disease induced by intrastriatal injection of rotenone.
    Khadrawy YA; Mourad IM; Mohammed HS; Noor NA; Aboul Ezz HS
    Gen Physiol Biophys; 2017 Jan; 36(1):99-108. PubMed ID: 27901474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of caloric vestibular stimulation in improvement of motor symptoms and inhibition of neuronal degeneration in rotenone model of Parkinson's disease - An experimental study.
    Thanalakshmi J; Archana R; Senthilkumar S; Shakila R; Pazhanivel N; Subhashini S
    Physiol Int; 2020 Oct; 107(3):390-405. PubMed ID: 33021954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.
    Requejo C; Ruiz-Ortega JA; Cepeda H; Sharma A; Sharma HS; Ozkizilcik A; Tian R; Moessler H; Ugedo L; Lafuente JV
    Mol Neurobiol; 2018 Jan; 55(1):286-299. PubMed ID: 28840482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia.
    Ikram H; Haleem DJ
    Pak J Pharm Sci; 2019 Mar; 32(2):555-562. PubMed ID: 31081766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonergic dysfunction in a model of parkinsonism induced by reserpine.
    Leal PC; Bispo JMM; Engelberth RCGJ; de A Silva KD; Meurer YR; Ribeiro AM; Silva RH; Marchioro M; Santos JR
    J Chem Neuroanat; 2019 Mar; 96():73-78. PubMed ID: 30597197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
    McIntyre IM; Kuhn C; Demitriou S; Fucek FR; Stanley M
    Psychopharmacology (Berl); 1983; 81(2):150-4. PubMed ID: 6415746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.